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Instruments of health and harm: how the procurement of 




Many healthcare goods, such as surgical instruments, textiles and gloves, are manufactured in 
unregulated factories and sweatshops where, amongst other labour rights violations, workers 
are subject to considerable occupational health risks. In this paper we undertake an ethical 
analysis of the supply of sweatshop-produced surgical goods to healthcare providers, with a 
specific focus on the National Health Service of the United Kingdom. We contend that while 
labour abuses and occupational health deficiencies are morally unacceptable in the production 
of any commodity, an additional wrong is incurred when the health of certain populations is 
secured in ways that endanger the health and wellbeing of people working and living 
elsewhere. While some measures have been taken to better regulate the supply chain to 
healthcare providers in the UK, further action is needed to ensure that surgical goods are 
sourced from suppliers who protect the labour and occupational health rights of their workers.  
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For those of us living in the United Kingdom (UK) one of the most obvious effects of 
economic globalisation is that the products we have come to rely upon are generally sourced 
and processed where labour and raw materials are inexpensive and readily available. However, 
cheap production costs frequently track poor labour regulation and/or weak enforcement of 
existing regulation [1–3] , which raises concerns about justice for workers. These concerns 
have led to high-profile campaigns in favour of ethical trade across various industries (such as 
mining, garments or agricultural products), but despite the fact that poor working conditions 
have also been observed in global procurement networks within the healthcare industry, this 
sector has received little attention or critique.  
 
Over a decade ago, it was revealed that the provision of goods to healthcare systems in high 
income countries (HICs) often involves products manufactured under precarious labour 
conditions, including surgical instruments and medical gloves [4, 5]. While some procurers 
and buyers have made efforts towards addressing this, they represent a very small proportion 
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of global healthcare purchasing [6]. Work is still needed to guarantee that healthcare goods 
across the world are ethically sourced, and that they do not damage the health, wellbeing and 
socio-economic prospects of those who manufacture them. 
 
The manufacture of healthcare products in precarious working conditions is concerning 
because all instances of precarious work are concerning, but also because benefitting from the 
harms experienced by others is morally problematic. In the case of healthcare-related goods 
there is a further specific injustice, and it is this which our paper focusses on. We argue that it 
is particularly troubling to make use of healthcare goods which can facilitate or enhance the 
health and wellbeing of some, but which were produced under conditions which jeopardise 
the health and wellbeing of those who made them (and that of their dependants). We show 
that the use of healthcare products produced under poor working conditions amounts to an 
extraction of good health and economic prospects from particular social groups in order to 
accentuate the health and economic outcomes of other groups, or the production of good health 
in one region at the expense of negative health outcomes in other regions. This trend 
exemplifies the way in which health systems and governments not only accept, but also benefit 
from health inequality, which constitutes an extraction of value not unlike the appropriation 
of resources which underwrites global inequality more generally. We conclude that it is 
immoral for nation-states and healthcare systems to seek to deliver good health to some at the 
cost of poor health and economic prospects to others, and recommend that governments take 
additional measures to ensure that their products were not produced in ways which endanger 
the health and wellbeing of workers and their dependents. 
 
In the interest of retaining a sharp focus within this paper, we will not discuss manufacture 
and distribution of personal protective equipment (PPE), where supply chains have come 
under unprecedented pressure during the current COVID-19 pandemic. Whereas many of our 
arguments can be applied to the supply of PPE (and other scholars may take up the task of 
discussing these more specifically), our study highlights issues that apply to surgical supply 
chains more broadly (including, but not limited to, PPE). We also do not describe here the 
moral issues relating to precarious employment and unregulated sweatshop or factory work 
more generally. Others have done so elsewhere (see e.g. [7-9]). Rather, we start from the 
premise that such work is morally unacceptable, and focus on the particular wrong that is 
committed in the procurement of healthcare products produced under these conditions. 
Further, while ethical shortcomings have been identified in the production of a range of 
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healthcare goods, here, we focus specifically on surgical goods. Our paper discusses these 
issues in the context of the United Kingdom’s National Health Service (NHS). Not only are 
the authors based in the UK, but as a health system funded by general taxation and national 
insurance contributions, the ethics of procurement within the NHS is a matter of public 
interest. 
 
Our article is structured as follows. In the next section we offer some background on global 
surgical procurement and supply chains, describe the evidence for unethical labour in the 
manufacture of surgical goods, and critically outline some of the efforts made in the UK to 
address these concerns. In the following section, we describe and critique the unjust global 
distribution of health, noting that the production of good health in high-income settings too 
often depends on poor health outcomes in low-income settings. The final section concludes by 
making recommendations for healthcare goods procurers, specifically, that these goods are 
fairly traded and only sourced from producers and suppliers who put in place systems to 
protect the occupational health and wider labour rights and entitlements of their workers.   
 
UNETHICAL LABOUR PRACTICES IN THE PROCUREMENT OF SURGICAL 
GOODS 
 
The global market for surgical instruments was estimated to be worth USD 5.9 billion in 2013 
[10], rose to USD 10.70 billion in 2017 [11] and it is expected to reach USD 38.3 billion by 
2025 [12]. In 2016, surgical sutures, staples, and staplers constituted the largest share of this 
market, followed by obstetrics, gynaecology and cardiovascular instruments, owing to the 
large number of caesarean surgeries being performed worldwide and the rising prevalence of 
chronic diseases. Canada and the USA dominated the global market, followed by Europe (in 
particular Germany and the UK), Japan, China, India, Brazil and Mexico [12, 13]. The leading 
suppliers of these surgical goods to Europe are registered in the USA, the Netherlands and 
Belgium, followed by several low and middle income countries (LMICs) that directly export 
substantial volumes of surgical instruments to this region – mainly Mexico, China, Malaysia, 
Costa Rica, Thailand, Pakistan, India and Vietnam. In 2015, the majority of procurement to 
Europe proceeded through long chains of buyers and intermediaries, while 12% of imports 




In the UK, the exact expenditure on surgical goods within the NHS is not publicly available, 
but the procurement of surgical goods and services stood at £30 billion annually in 2015 [15], 
with the total healthcare expenditure (from both public and private sectors) standing at £197.4 
billion in 2017 [16]. As with many other healthcare providers worldwide, procurement in the 
UK occurs through direct supply or via local, regional or national procurement hubs which in 
turn rely on suppliers or intermediaries at national, regional and international levels. In 
England, the largest procurement hub for surgical goods is the NHS Supply Chain, which has 
awarded contracts to UK and overseas suppliers importing goods from factories and 
sweatshops around the world. Regardless of their country of formal registration, many 
suppliers to the NHS outsource the manufacture of their products to international suppliers, 
mainly from: the US and Europe (disposable products and textiles); Mexico (dressings and 
plastic-based products such as gloves and masks); and Asia (textiles, dressings, gloves, 
surgical instruments, syringes, needles, etc.) [15]. In the case of the gloves used every day in 
NHS clinics and operating theatres, most production is outsourced to factories in Malaysia and 
Thailand [17], whilst a significant proportion of metal surgical instruments used in the UK are 
produced in the city of Sialkot, in north-eastern Pakistan [18]. 
  
With the slogans “delivering value to the NHS,” “better procurement, better value, better care” 
and “doing it right: savings without compromising on care” [19], the procurement strategy of 
the NHS Supply Chain has traditionally focused on making savings through price comparisons 
and benchmarking. For instance, as an example of “efficient procurement” and of “doing 
things right,” the 2013 procurement strategy advises that the NHS could generate savings of 
up to 38 per cent on the approximately £25 million spent on sterile surgeon’s gloves by 
undertaking product/producer substitution. The document goes on to suggest that these savings 
could be used to reduce the reliance of the NHS on costly agency staff, or could be a major 
driver for growth in the economy.  
 
In other words, the procurement strategy is dominated by considerations of cost-cutting, and 
“doing things right” is meant in the narrow sense of ensuring that quality goods are obtained 
at the lowest possible price, an objective which is deemed to be in the public interest. While 
cutting the expenses associated with healthcare goods may be considered a prudent strategy 
for the NHS, which is after all answerable to the taxpayers who fund it, there are morally 
relevant externalities that are absent from this narrative. Aggressive price comparison and 
global supply competition are known to have a significant effect on workers’ labour conditions 
5 
 
and health and safety, producing and perpetuating jobs that are very often precarious, insecure 
and unhealthy [20, 21]. As this global competition pushes governments, manufacturers, and 
suppliers to lower prices, basic labour rights are overlooked in order to attract buyers and 
procurement contracts [1, 20]. As the next subsection illustrates, the thousands of healthcare 
goods used every day to promote health and economic prospects in the UK too often damage 
the health and socio-economic prospects of people living and working elsewhere. 
 
Labour and occupational health violations in the manufacture of surgical goods 
 
Produced in cooperatives, unregulated factories, or sweatshops in Pakistan, Mexico, Thailand 
or the USA, the jobs generated under this open global competition are often unregulated, 
insecure and highly unhealthy [1, 3, 6], and often imperil, rather than safeguard, the health and 
wellbeing of workers and their dependants both in the short and long-term. This tends to be 
the case whether or not states have ratified the International Labour Organization’s (ILO) 
conventions [18] and regardless of the existence of adequate legislation and enforcement 
mechanisms [1, 21]. Since 2007, NGOs such as the British Medical Association, Swedwatch 
and Finnwatch have produced reports on labour rights violations and precarious employment 
in the healthcare manufacturing sector which supplies the NHS. The most notable examples 
are the Pakistani surgical instruments and Malaysian gloves manufacturing industries. In 
Pakistan, the manufacture of surgical instruments is associated with non-compliance with local 
labour laws with regard to minimum wage and excessive overtime, unfair contractual 
obligations, widespread child labour, and an absence of health and safety protections [4, 5, 
18]. In Malaysia, the gloves industry is associated with ad-hoc employment, poor 
remuneration, compulsory overtime, insufficient health and safety provisions, anti-union 
activities and bonded labour of migrant workers involving illegal retention of passports [17].  
 
There is little information regarding the specific disease burden associated with working on 
these production lines and, as happens with other industries, attempts at measuring this burden 
are often obstructed by suppliers, buyers, producers, and/or governments themselves [20, 21]. 
The limited available evidence indicates that in the manufacture of surgical instruments in 
Pakistan, musculoskeletal problems and injuries are common, sometimes leading to significant 
impairment, including loss of limbs [5]. There are serious dangers at various stages of the 
manufacturing process, including exposure to heavy machinery, hazardous electrical wiring, 
toxic and corrosive chemicals, metal dust and deafening noise-levels in grinding rooms [5, 
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18]. When unmanaged, these occupational hazards can cause cuts and burns to hands and feet, 
repetitive strain syndrome, trauma to the eye, noise-induced hearing loss, visual loss, electric 
shocks, chronic obstructive pulmonary disease, or lung cancer [22]. However, as employers 
are able to freely curb collective-bargaining rights with anti-union policies [18], 
disempowered workers in need of an income often operate machinery that is not regularly 
checked without any personal or collective protective equipment [18]. Further, workers’ wages 
are insufficient even by Pakistan’s own household income standards [5] and therefore do not 
permit regular contributions to social insurance mechanisms that could enable workers access 
to healthcare or disability benefits.   
 
The manufacture of other healthcare goods presents similar risks. For instance, the 
manufacture of healthcare textiles has been associated with silicosis and lung cancer, while 
unprotected glove-manufacturing is associated with exposure to chemical products, 
temperatures above 45°C (and sometimes as high as 70°C), noise levels that can cause hearing 
loss, skin and eye burns, fume inhalation, and other physical impairments associated with 
repetitive motion and frequent lifting [17]. 
 
In spite of these harms, as happens with other industries, many governments bend existing 
legislation in their efforts to increase much-needed local and national employment and 
economic opportunities, manufacturing companies accept these deals to maintain or expand 
their operations, and poor and disempowered job-seekers often pursue these jobs in the 
absence of alternatives [20, 21]. In order to remain competitive and maintain profits, many 
suppliers continue to cut costs by outsourcing production to locations where lower wages will 
be accepted and labour and occupational health regulations can be disregarded [23]. To 
maintain contracts with buyers, some industries (e.g. Mexican surgical masks manufacturers) 
have further reduced production costs through eliminating factory operations and instead 
relying on hundreds of home-workers who receive no employee benefits and only an insecure 
income [15]. 
 
Existing efforts towards ethical procurement in the NHS 
 
Since 2009, ethical sourcing within the NHS Supply Chain has been guided by the Supplier 
Code of Conduct (SCC), which outlines basic standards in relation to labour rights and worker 
wellbeing. According to the NHS Supply Chain, this code is a contractual requirement and 
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any violation of the obligations it stipulates are considered a breach of contract by the supplier 
[24]. In response to evidence of continued labour right violations since the implementation of 
the SCC, the NHS Supply Chain worked closely with various industry bodies and ethical trade 
organisations to develop the Labour Standards Assurance System (LSAS) in 2011. The LSAS 
is intended to support the SCC for products where there are documented labour rights 
violations, such as surgical instruments, gloves and textiles [17, 18]. Piloted in 2012 in relation 
to surgical instruments, LSAS requires suppliers in the NHS supply chain to demonstrate they 
have systems in place to guarantee the labour rights and human rights of workers, and helps 
them to develop rectification plans when necessary. Strengthened by the Modern Slavery Act 
2015, which makes companies accountable for labour abuses occurring along their whole 
chain of operations, the SCC and LSAS quickly became the cornerstone of the NHS Ethical 
Procurement Strategy.  
 
These recent regulatory changes have led to small demonstrable improvements in some 
workers’ lives. For example, some surgical instrument suppliers subject to the LSAS 
requirements in Pakistan have demonstrated efforts towards improving labour standards, 
including minimum wages and paid overtime [18]. Glove manufacturing audits have also 
indicated some improvement to working conditions, including formalised contracts, some 
leave entitlement and minimum wage as per national regulations [17]. However, these 
advances are neither widespread nor lasting, and several counts of non-compliance were 
observed during visits to factories in both Pakistan and Malaysia, primarily regarding working 
time, production targets and safety measures [17, 18]. Recent media reports have also revealed 
continued abuse of migrant workers in the Malaysian gloves manufacturing sector, including 
in factories that are subject to the LSAS standards required by the NHS Supply Chain [17]. 
When asked about the challenges they face, Pakistani factory owners and managers 
highlighted the negative impacts that low payments and volatile contracts have on their ability 
to comply with labour regulations and invest in safety measures: “…buyers need to understand 
the costs. They do not want to pay much but have lots of demands. Without sustainable 
contracts and prices how is it possible for us to improve?” [18]. Clearly, a key challenge to 
ethical procurement for the NHS is the NHS Supply Chain’s single-minded emphasis on 
maximising savings.  
 




The moral concerns associated with the global system of healthcare goods procurement are 
various and extend beyond the mere physical health of workers. As Bhutta writes in relation 
to labour rights violations in the production of surgical goods: 
 
Poor labour conditions should concern all those in health care. Work is inextricably 
correlated to physical and mental well-being: unsafe working conditions risk bodily 
injury; inadequate remuneration links to malnutrition, poor housing and lack of 
opportunity. Long or irregular working hours and a lack of respect at work contribute to 
stress, anxiety and depression [6]. 
 
Globally, most people spend at the very least a third of their adult lives working. The risks and 
rewards of that work are strongly determinative not only of the quality of life, health 
possibilities and economic prospects of individual workers, but also that of their dependants 
and communities. The risks and rewards of work therefore determine the socio-economic 
prospects of individuals and nations alike. However, some forms of work are more health-
endangering than others. As described in the previous section, the current production of 
surgical instruments and gloves is particularly health-endangering for workers and traps them 
and their dependents in cycles of poverty and ill-health. That is ethically concerning in its own 
right, as part of a broader concern about failures to protect the occupational health and labour 
rights of low-paid, disempowered workers. But the extent and nature of the ethical concerns it 
raises change in important ways when one also considers that the intention and the outcome 
of the production of healthcare goods is to improve the health of those within recipient 
populations. Under the current system, the workers who produce surgical goods have their 
health outcomes suppressed via a range of risks to their occupational health and other labour 
violations, while those for whom the healthcare goods are procured have their health outcomes 
enhanced.  
 
Healthcare goods such as gloves and surgical instruments facilitate and enhance the health of 
many. Having a large stock of sterile gloves and of (often disposable) surgical instruments 
helps to optimise the safety of clinical examinations and procedures, and minimise the risk of 
infection. As such, these goods make safe, optimal healthcare possible for those whose 
healthcare services procure sufficient amounts of these resources. Further, some goods (e.g. 
clinical gloves) are an occupational health measure, as they also protect healthcare workers 
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from discomfort, infection, or exposure to toxic substances, therefore healthcare workers also 
experience a positive health effect as a result of the use of healthcare goods. This is particularly 
important since the point can be made even more precisely, in that the occupational health of 
those who produce surgical instruments is endangered even as they produce items that are 
essential to the occupational health of other workers. This contradictory feature of healthcare 
goods has become particularly evident during COVID-19 public health crisis. As the global 
demand for gloves and masks has risen exponentially, manufacturing factories have upscaled 
production in precarious conditions despite nationwide lockdowns [25]. 
 
Much like healthcare goods, the occupational health and safety of workers becomes, in this 
manner, a commodity itself [21]. This is most vivid when noting that elsewhere in the world, 
there are shortages of the very same healthcare goods that are so widely available in other 
settings. For example, shortages of medical gloves have been reported in Nigeria, Indonesia, 
Zambia, Tanzania, and Bangladesh [26-30], and shortages of surgical instruments in Brazil, 
Nigeria, Kenya, Ethiopia and Honduras [31-33]. As a result of these shortages, some 
procedures are delayed or precluded, or take place with increased infection risks to service 
users and clinicians. Even more concerning is the fact that there are severe shortages of 
healthcare goods in settings known to be significant global producers and exporters. For 
instance, while Argentina manufactures surgical goods for export to Brazil, many regions in 
the country (mostly rural and peri-urban) suffer from shortages [13]. Similarly, whilst Mexico 
is the eighth largest global exporter of healthcare goods, the goods produced are not accessible 
within the Mexican public health system, so that only the 6% of the population with access to 
private-sector healthcare can benefit from these products [34]. A similar situation has been 
noted in Pakistan. Effectively, the workers manufacturing these products (and their 
dependents) are amongst those least likely to benefit from them. Worse, manufacturing 
countries often end up purchasing the final products from importing countries [13]. 
 
In the next subsection, we explore the broader context of global health inequality, and show 
that the conditions under which healthcare goods are manufactured point to several specific 
injustices which warrant urgent redress. 
 




A public good is a physical or non-physical resource or service that meets human needs or 
desires and is non-excludable and non-rivalrous [35]. A good being non-excludable means 
that it is not possible to prevent those who do not pay from benefitting from the good; a good 
being non-rivalrous means that one person or group’s use of the good does not reduce the 
utility of the good to others. Herd immunity to an infectious disease is a public good, and is 
easily established to be both non-rivalrous and non-excludable, likewise for clean air, street 
lighting, pavements, and certain forms of knowledge. Well-funded, free, universal health-
care—i.e., the NHS in principle, if not in practice—may be argued to be a public good. It is 
non-excludable, since everyone who is ordinarily resident in the UK qualifies for it regardless 
of their level of contribution, and it is non-rivalrous, since (provided it is well-funded), no one 
person’s use of the service precludes anyone else’s.   
 
Even if one can argue that healthcare is a public good in the UK (and we will not attempt to 
take up this challenge here), one certainly cannot argue that health itself is a public good. 
Healthcare is only one determinant of a person’s health, and is often not the most important. 
Together with rights and entitlements, diet, exercise, living conditions, occupation, socio-
economic status, ethnicity, and gender (amongst other factors) are strongly determinative of a 
person’s health possibilities [2, 36]. Since these contributors are manifestly not public goods, 
health itself cannot be a public good, rather, it is a good that is rivalrous and excludable to the 
extent that these determinants are affected by factors that are rivalrous and excludable, notably, 
economic considerations which are definitionally so. Understanding health inequalities 
therefore requires attention to its political economy, especially since healthcare and other 
health determinants are increasingly marketised and privatised within an ever more globalised 
economy [37]. Political economy approaches to health are perhaps best expressed by Nancy 
Krieger, who writes that “analysis of causes of disease distribution requires attention to the 
political and economic structures, processes and power relationships that produce societal 
patterns of health, disease, and wellbeing via shaping the conditions in which people live and 
work” [38] (p. 168). 
 
At the global scale, health outcomes in different world regions vary dramatically. One can see 
this for instance in the thirty-four year gap between the life expectancy of Japan, at the top of 
the life-expectancy table, and Sierra Leone, at the bottom [39]. The wealth of Global North 
states enables the health of their citizens; the poverty of Global South states tends to limit the 
health of their citizens, and a similar dipole is observed within nation-states where socio-
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economic inequalities determine in-country health inequities. Importantly, the wealth of 
certain world regions and populations is related to the poverty of others, notably through 
histories of colonialism, and the present-day neo-colonial global economic system, which 
tends to concentrate capital in Global North states and corporations [40]. As Benatar et al. 
note, “the present dominance of perverse market forces on global  health” has led to a situation 
in which “disparities in wealth and health have persisted and, in many places, widened” [41] 
(p. 646). Globally, health is excludable, rivalrous and uneven because wealth and power are 
excludable and rivalrous, and are vastly unequal at the global scale.  
 
In this article we are concerned with one particular case within a variety of ways in which 
health is rivalrous: a reduction in the health of one group is related to an improvement in the 
health of another group. Such cases seem particularly pernicious, since it is morally troubling 
that the health of one group should ever be facilitated at the expense of another’s.  
 
There are some important analogues to consider. First, the international “brain drain” of health 
workers, in which those who are trained in lower-income countries, often at the expense of 
tax-payers, migrate in search of higher pay, health entitlements and better living and working 
conditions, and therefore end up benefitting the health of those in destination states, while 
leaving their own communities with stark shortages of health-workers [42]. This seems even 
more problematic when one considers the inconsistency of the migration of medical workers 
into the NHS and the increasingly draconian restrictions on migrants’ access to free NHS care. 
Clearly, achieving good health for some groups is deemed to justify the poaching of health-
workers from communities with a dire need for them, but the people of those communities 
may not access high-quality health-care if they migrate [43]. Consider also environmental 
racism and classism, where polluting activities take place close to, or within, the 
neighbourhoods of those with low socio-economic status, thereby decreasing their health 
possibilities in order to protect the health possibilities of those of higher social status [44]. 
Finally, consider the global waste trade, in which high income states pay lower income states 
to dispose of, or recycle, their waste, including healthcare waste [45] and items that are toxic 
[46]. It has been reasoned that the cost to the health of those in the Global North renders in 
situ disposal not worthwhile, given the priorities of Global North people, while the sums that 




To see more clearly why these cases are particularly morally concerning, consider the 
following thought experiment: a new machine is invented that filters dangerous pollutants 
from the air of a particular wealthy neighbourhood, improving the air quality and therefore the 
health of those who live in this area. However, the machine requires a team of workers to 
continually clean the filters, releasing high concentrations of pollutants which they cannot 
avoid inhaling, causing serious health problems. It seems morally intuitive that we should 
reject such a “health-improving measure” given that it is in fact health-endangering for some. 
Indeed, calling such a machine a “health-improving measure” would be a misrepresentation 
of its total effects, and would amount to an admission that the health of some people was more 
important than the health of others, which points to an obvious injustice.1  
 
In principle, health need not be rivalrous, since resources could be distributed in such a way 
as to ensure that everyone had equitable and adequate access to the determinants of good health 
(see e.g. [48]). In the current global economic system, the determinants of health are closely 
tied to the distribution of wealth and other predictors of quality of life (including labour 
protections), with the result that good health for some is often secured in ways that negatively 
affect health for others, as in the examples just described. This analysis can also be applied to 
health-enhancing healthcare goods, which are produced in health-endangering work 
environments, where the mandate that profits be optimised is prioritised over all other 
considerations. The obvious moral lens through which to understand this injustice is 
cosmopolitanism—the idea that moral consideration transcends national borders [49, 50]. This 
is appropriate when considering health-enhancing products that rely on workers from other 
states and regions within a globalised economy.  
 
Cosmopolitanism requires that we do not favour one group’s claims to health above another’s 
merely on the basis of geography or any other contingent factor, so that the health-enhancing 
effects of healthcare goods must be considered alongside the health-endangering aspects of 
their production, regardless of the physical distance between the sites of benefit and harm or 
the citizenships of those affected. Cosmopolitanism also demands that we start from the 
assumption that the health needs of every person, regardless of their nationality, is equally 
                                                          
1 A utilitarian might argue that the machine would be justifiable if the beneficiaries of the clean air sufficiently 
outnumbered the workers harmed by it, or if the harms to the workers were relatively minor, but these 
arguments would be more forceful if the workers were equipped with high standard protective gear to mitigate 
the risks they face, which dovetails with the argument we are making.  
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important. It then follows that a health system that manages to provide a high standard of 
healthcare to its citizens because it economises by relying on products which harm citizens 
elsewhere is acting unjustly. If health is to be understood as rivalrous, then health justice 
requires all actors to be sensitive to the ways in which the improvement of health in some 
contexts might harm health in other contexts. This is in contrast to a “statist” perspective, in 
which one sees the UK or the NHS as having special or limited obligations to its own citizens 
or users, and companies or government of states in which healthcare products are 
manufactured as having sole responsibility for their workers or citizens (see e.g. [51, 52]). 
Given that health is a rivalrous good which is sought against the backdrop of a globalised 
economy, we contend that statism is an inadequate lens through which to seek health justice, 
particularly in the case under study. 
 
Finally, it is worth noting that while other forms of work may also involve serious risks and 
burdens for the benefit of others (e.g. a nurse working on an infectious disease ward), consider 
that the protections offered to those producing healthcare goods are woefully inadequate, while 
those working in other professions and contexts tend to have protections and (sometimes) 
remuneration which reflect the risks and burdens they face. We can therefore say that while 
many workers face burdens and risks, some burdens and risks are unjust.    
 
In short, we should be concerned about whether the production of healthcare goods is worth 
the cost to those who make them, and whether they are improving health as a whole, rather 
than just for some people. Of course, the answer lies not in rejecting masks, gloves, and 
instruments, but rather in ensuring that the conditions of their production are such that 
avoidable risks to the health and wellbeing of workers are minimised. We turn to this in the 
next section.  
 
THE CASE FOR ETHICAL PROCUREMENT IN THE NHS 
 
The pursuit of health and socio-economic benefit within some contexts at the expense of the 
health of people elsewhere raises serious moral issues. Returning to the particular case of 
healthcare goods procurement, the NHS stands accused of contributing to health inequality, 
and producing health in its own jurisdiction via the obstruction of good health in contexts 
where health outcomes are already inadequate. In this final section, we combat an important 
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counter-argument, and present the case for more robust, committed ethical procurement 
practices within the NHS.  
 
As we have seen, one can argue that in a publicly-funded health system there is a responsibility 
to obtain maximum value from public funds, which means purchasing quality healthcare goods 
at the lowest cost, even if doing so encourages global competition of prices and invokes 
complicity in the associated labour right violations. In other words, all other considerations 
are taken to be secondary to the prudent use of public money. After all, one could argue, the 
greater the saving, the greater the ability of the NHS to provide quality healthcare to a greater 
number of people. Further, other parties are also complicit in the harms to their workers or 
citizens, i.e. foreign governments, factory owners, and factory management.  
 
Yet the NHS, while described as a “national” health service, is not exempt from the duty to 
consider moral issues beyond national borders. After all, as we have already noted, the NHS 
is critically dependent on workers trained outside the UK. Consider that half of newly 
registered doctors in 2018 were trained abroad [53], many from nations with severe shortages 
of health workers, and whose training costs were subsidised by other states. While the NHS is 
tasked with the objective of keeping people in its own jurisdiction healthy, its right to realise 
this function stops at the point at which it begins to infringe on the right of other states, health 
systems, or communities to keep their people healthy [43]. In this case, the NHS relies on 
particular goods whose production restricts the health outcomes of factory workers.  
 
Further, we do not deny here the shared responsibility of other actors—foreign governments, 
factory owners, and factory management—but our focus is on the particular wrong that is 
committed by the NHS as a global procurer and as a public health body. Not only is the NHS 
committed to the production of good health, but as a major procurer, it plays a particularly 
influential role in the supply chain, and has the potential to model responsible behaviour for 
other health systems. As recognised by the UK Slavery Act 2015, since pricing and other 
contractual stipulations are set by a main purchaser, they often have the greatest power, and 
therefore responsibility, to guarantee that rights are complied with in their supply chains.  
 
As it stands, the duty to avoid causing harm while promoting health is not being adequately 
realised within the NHS. Whilst there is evidence of NHS supply contracts being terminated 
because of global price comparisons and producer substitutions, as of 2017 only one contract 
15 
 
had been terminated due to labour rights violations, despite evidence of many such cases [6]. 
In fact, the NHS Supply Chain’s emphasis on efficient procurement based on continued 
savings and producer substitution [19] hampers the NHS’ ability to abide by its own 
regulations and efforts regarding working conditions in its supply chains. To address these 
issues, we recommend that the NHS prioritise the following: a) paying fair prices even if this 
means paying slightly more for the same product; b) eliminating chains of intermediaries by 
prioritising direct contracts with manufacturers; c) establishing product/producer substitution 
based on labour rights compliance rather than on manufacturers and suppliers’ ability to 
continuously lower prices and production costs; and d) ensuring transparency in its supply 
chains, and in particular: informing the public that the products used to secure their health 




The uneven global distribution of health is exacerbated by the extraction of health from certain 
settings and social groups to the benefit of others. In this paper we have explored a particular 
instance of this trend by critically examining the moral issues raised by current global 
procurement chains of healthcare goods, with a focus on the NHS. We have described the 
various labour and occupational health violations faced by those who produce healthcare 
goods, and have shown that the NHS is implicated in these harms through its procurement 
practices, which focus on driving down costs, with insufficient regard for the conditions under 
which the goods are produced. Health systems in high-income contexts have a duty to ensure 
that they do not exacerbate global health inequality, and can do so by ensuring that the products 
used to ensure health of people in their jurisdictions do not threaten the health of others living 
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